Atara Biotherapeutics Inc. Common Stock (NASDAQ:ATRA)

Home >> Stock >> Atara Biotherapeutics Inc. Common Stock >> Metrics

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California....

+See More
See More

Blog+More

The Sino-American trade war may slash global GDP by $600 billion.

Monica McNeil

2019-06-15 10:28:00 Saturday ET

The Sino-American trade war may slash global GDP by $600 billion.

The Sino-American trade war may slash global GDP by $600 billion. If the Trump administration imposes tariffs on all the Chinese imports and China retaliate

+See More

Persistent post-Roman European fragmentation leads to modern economic growth and development.

Jacob Miramar

2023-10-21 11:32:00 Saturday ET

Persistent post-Roman European fragmentation leads to modern economic growth and development.

Walter Scheidel indicates that persistent European fragmentation after the collapse of the Roman Empire leads to modern economic growth and development.

+See More

Corporate cash management

Jacob Miramar

2022-03-25 09:34:00 Friday ET

Corporate cash management

Corporate cash management The empirical corporate finance literature suggests four primary motives for firms to hold cash. These motives include the tra

+See More

Response to USPTO fintech patent protection and accreditation

Andy Yeh Alpha

2023-01-09 10:31:00 Monday ET

Response to USPTO fintech patent protection and accreditation

Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent

+See More

President Trump tweets his key decision to oust State Secretary Rex Tillerson due to intense disagreement over diplomatic affairs.

Fiona Sydney

2018-03-07 07:34:00 Wednesday ET

President Trump tweets his key decision to oust State Secretary Rex Tillerson due to intense disagreement over diplomatic affairs.

President Trump tweets his key decision to oust State Secretary Rex Tillerson after several months of intense disagreement over diplomatic affairs. Trump so

+See More

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates.

Fiona Sydney

2024-05-27 03:23:34 Monday ET

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates.

Stock Synopsis: Life insurers emphasize profit margins over sales growth rates. We review and analyze the recent market share data in the U.S. life insur

+See More